Literature DB >> 28068638

Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer.

Weibo Xu1, Junkai Chang1, Guangchao Liu2, Xinyi Du1, Xiaodong Li3.   

Abstract

Fork-head box R2 (FOXR2), a member of FOX protein family, was reported to play important roles in the development and progression of cancers. However, the expression and function of FOXR2 in prostate cancer remain unclear. In this study, we investigated the role of FOXR2 in prostate cancer and cancer progression including the molecular mechanism that drives FOXR2-mediated oncogenesis. Our results showed that FOXR2 was overexpressed in prostate cancer cell lines. The in vitro experiments demonstrated that knockdown of FOXR2 significantly repressed the proliferation, migration and invasiveness of prostate cancer cells. Furthermore, the in vivo experiments indicated that knockdown of FOXR2 significantly attenuated prostate cancer growth. Finally, knockdown of FOXR2 significantly down-regulated the protein expression levels of β-catenin, cyclinD1 and c-Myc in DU-145 cells. Taken together, our results demonstrated for the first time that FOXR2 plays a critical role in cell proliferation and invasion, at least in part, through inhibiting the Wnt/β-catenin signaling pathway during prostate cancer progression. Thus, FOXR2 may be an attractive therapeutic target for the treatment of prostate cancer.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Fork-head box R2 (FOXR2); Invasion; Proliferation; Prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28068638     DOI: 10.1016/j.biopha.2016.12.120

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Circ-PGC increases the expression of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer.

Authors:  Daokui Xia; Zhen Chen; Quan Liu
Journal:  Cell Cycle       Date:  2021-09-08       Impact factor: 5.173

2.  miR-202 Suppresses Cell Proliferation by Targeting FOXR2 in Endometrial Adenocarcinoma.

Authors:  Xinchao Deng; Congzhe Hou; Zhen Liang; Huali Wang; Lin Zhu; Hui Xu
Journal:  Dis Markers       Date:  2017-07-30       Impact factor: 3.434

3.  CircABCB10 promotes nonsmall cell lung cancer cell proliferation and migration by regulating the miR-1252/FOXR2 axis.

Authors:  Xufeng Tian; Lin Zhang; Yan Jiao; Junsheng Chen; Ying Shan; Wenfeng Yang
Journal:  J Cell Biochem       Date:  2018-11-11       Impact factor: 4.429

Review 4.  Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities.

Authors:  Pauline J Beckmann; David A Largaespada
Journal:  Int J Mol Sci       Date:  2020-02-10       Impact factor: 5.923

5.  Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.

Authors:  Yangle Li; Xiongbing Zu; Xiheng Hu; Long Wang; Wei He
Journal:  Med Sci Monit       Date:  2019-11-25

6.  Mechanism of piR-DQ590027/MIR17HG regulating the permeability of glioma conditioned normal BBB.

Authors:  Xue Leng; Jun Ma; Yunhui Liu; Shuyuan Shen; Hai Yu; Jian Zheng; Xiaobai Liu; Libo Liu; Jiajia Chen; Lini Zhao; Xuelei Ruan; Yixue Xue
Journal:  J Exp Clin Cancer Res       Date:  2018-10-11

7.  circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.

Authors:  Shu Zhang; Jie Cheng; Chenlian Quan; Hao Wen; Zheng Feng; Qin Hu; Jun Zhu; Yan Huang; Xiaohua Wu
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-18       Impact factor: 8.886

8.  FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome.

Authors:  Felix Schmitt-Hoffner; Sjoerd van Rijn; Umut H Toprak; Monika Mauermann; Felix Rosemann; Anke Heit-Mondrzyk; Jens-Martin Hübner; Aylin Camgöz; Sabine Hartlieb; Stefan M Pfister; Kai-Oliver Henrich; Frank Westermann; Marcel Kool
Journal:  J Clin Oncol       Date:  2021-06-10       Impact factor: 50.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.